Embecta is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes, primarily selling to wholesalers and distributors. The company is strengthening its core business through its brand transition program in international markets, expecting significant completion by the end of calendar year 2026.
Embecta reported Q1 FY2026 profits of $44.1 million ($0.74 per share) on sales of $261.2 million, with a sales decline of 0.3% year-over-year but recovery from breakeven. The company reaffirmed 2026 guidance of $1.071-$1.093 billion in sales and adjusted EPS of $2.80-$3.00. However, the company faces offsetting declines in the U.S. due to lower pricing from customers and competition, with pricing headwinds expected to push numbers toward the bottom of guidance.
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.
Open report →